Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells

Oncogenesis

Volumn 3, Issue 5, 2014, Pages

  Hibino, S ^a   Saito, Y ^a   Muramatsu, T ^a   Otani, A ^a   Kasai, Y ^a   Kimura, M ^a   Saito, H ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

cancer; DZNep; EZH2; microRNA; SAHA

Indexed keywords

3 DEAZANEPLANOCIN A; BMI1 PROTEIN; CYCLIN DEPENDENT KINASE 2; DYRK1A PROTEIN; GIRDIN; MICRORNA; MICRORNA 1246; MICRORNA 302A; MICRORNA 4448; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SOX2; TUMOR PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINT; GASTRIC CANCER CELL LINE; GENE ACTIVATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CANCER CELL LINE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84927709697     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.17     Document Type: Article

References (46)

1. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat res 2008; 647: 21-29.
2. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011; 19: 86-100.
3. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
4. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
5. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006; 5: 3096-3104.
6. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F et al. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol App Neurobio 2011; 37: 381-394.
7. Saito Y, Suzuki H, Hibi T. The role of microRNAs in gastrointestinal cancers. J Gastroenterol 2009; 44(Suppl 19): 18-22.
8. Saito Y, Saito H. MicroRNAs in cancers and neurodegenerative disorders. Front Genet 2012; 3: 194.
9. Saito Y, Saito H. Role of CTCF in the regulation of microRNA expression. Front Genet 2012; 3: 186.
10. Saito Y, Saito H, Liang G, Friedman JM. Epigenetic alterations and MicroRNA misexpression in cancer and autoimmune diseases: a critical review. Clini Rev Allergy Immunol. (e-pub ahead of print 21 December 2013).
11. Saito Y, Hibino S, Saito H. Alterations of epigenetics and microRNA in hepatocellular carcinoma. Hepatol Research 2014; 44: 31-42.
12. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443.
13. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009; 28: 2738-2744.
14. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14: 2115-2124.
15. Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res 2011; 39: 1054-1065.
16. Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res 2010; 70: 9473-9482.
17. Cai N, Wang YD, Zheng PS. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA 2013; 19: 85-95.
18. Zhang Y, Liao JM, Zeng SX, Lu H. p53 downregulates Down syndrome-Associated DYRK1A through miR-1246. EMBO Rep 2011; 12: 811-817.
19. Weng L, Enomoto A, Ishida-Takagishi M, Asai N, Takahashi M. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis. Cancer Sci 2010; 101: 836-842.
20. van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999; 23: 474-478.
21. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
22. Laguna A, Aranda S, Barallobre MJ, Barhoum R, Fernandez E, Fotaki V et al. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev Cell 2008; 15: 841-853.
23. Seifert A, Clarke PR. p38alpha-And DYRK1A-dependent phosphorylation of caspase-At an inhibitory site in response to hyperosmotic stress. Cell Signal 2009; 21: 1626-1633.
24. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
25. Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res 2008; 68: 1310-1318.
26. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Sci USA 2005; 102: 13944-13949.
27. Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-Apoptosis genes. Carcinogenesis 2012; 33: 1294-1301.
28. Zhai XF, Fang FF, Liu Q, Meng YB, Guo YY, Chen Z. MiR-181a contributes to bufalin-induced apoptosis in PC-3 prostate cancer cells. BMC Complement Altern Med 2013; 13: 325.
29. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y et al. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res 2011; 71: 2611-2621.
30. Wang Z, Liao H, Deng Z, Yang P, Du N, Zhanng Y et al. miRNA-205 affects infiltration and metastasis of breast cancer. Biochem Biophys Res Commun 2013; 441: 139-143.
31. Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 2013; 52: 70-78.
32. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, Chopp M. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 2010; 28: 1024-1030.
33. Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett 2013; 339: 260-269.
34. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 2008; 88: 1358-1366.
35. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010; 10: 367.
36. Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K et al. MicroRNAs in Hepatobiliary and Pancreatic Cancers. Front Genet 2011; 2: 66.
37. Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012; 72: 3631-3641.
38. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10: 400-405.
39. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012; 11: 1735-1746.
40. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012; 130: 2557-2567.
41. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-9218.
42. Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Diff 2012; 19: 232-244.
43. Ren J, Jin P, Wang E, Marincola FM, Stroncek DF. MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 2009; 7: 20.
44. Wang F, Xue X, Wei J, An Y, Yao J, Cai H et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer 2010; 103: 567-574.
45. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009; 8: 1579-1588.
46. Sato A, Saito Y, Sugiyama K, Sakasegawa N, Muramatsu T, Fukuda S et al. Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication. J Cell Biochem 2013; 114: 1987-1996.